Binding site

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Wednesday, January 31, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Multiple myeloma, EPS, COVID-19, Table, CSR, GAAP, STEM, Risk assessment, Thermo Fisher Scientific, Binding site, S/TEM, TMO, FDA, Laboratory, COVID-19 testing, Proteomics, Pre-eclampsia, Health equity, Electricity, Video game

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2023.
  • GAAP operating income for the fourth quarter of 2023 was $1.85 billion, compared with $1.86 billion in the year-ago quarter.
  • Adjusted EPS in the fourth quarter of 2023 was $5.67, versus $5.40 in the fourth quarter of 2022.
  • Adjusted operating income for the fourth quarter of 2023 was $2.55 billion, compared with $2.56 billion in the year-ago quarter.

‘Dean of Asian Myeloma’ Dr. Kazuyuki Shimizu to Receive First Asian Myeloma Network (AMN) Distinguished Service Award

Retrieved on: 
Saturday, October 21, 2023
Multiple myeloma, IMF, Doctor of Philosophy, Multimodal, JSM, Executive Committee, Panobinostat, Prognosis, Physician, Global Affairs Canada, Binding site, Patient, International Myeloma Foundation, Penn State Holy Spirit, Denosumab, MD, IMS, Research, Society, Memorial Sloan Kettering Cancer Center, EMN, AMN, Government, Holy Spirit Hospital (Makeni), Shangri-La Hotel, Bangkok, Memorial, Flow cytometry, Thalidomide, Nursing, Medical device, Cryptocurrency, Blood

The Asian Myeloma Network Distinguished Service Award was conceived to recognize and honor the lifelong achievements of deserving AMN myeloma specialists, who have made a considerable impact in the field of myeloma research, clinical trials, and patient support.

Key Points: 
  • The Asian Myeloma Network Distinguished Service Award was conceived to recognize and honor the lifelong achievements of deserving AMN myeloma specialists, who have made a considerable impact in the field of myeloma research, clinical trials, and patient support.
  • “As the first awardee for the AMN’s Distinguished Service Award, Prof. Shimizu is uniquely deserving as a dedicated and accomplished clinician and myeloma researcher.
  • He greatly assisted in the establishment of the Asian Myeloma Network by ensuring robust Japanese involvement and by leading discussions about structural and strategic plans for network activities.
  • The AMN Distinguished Service Award provides a spotlight to honor leading Asian myeloma specialists,” added Mr. Navid.

Thermo Fisher Scientific Announces the Launch of the EXENT® Solution with IVDR Certification

Retrieved on: 
Thursday, August 24, 2023
Research, Technology, Professional Services, Software, Biotechnology, Data Analytics, Health, Data Management, Science, Oncology, Mayo Clinic, IVDR, Serum, Multiple myeloma, Immunoglobulin M, Bone marrow, Immunoassay, GAM, Thermo Fisher Scientific, Immunoglobulin A, Binding site, The Advanced Visualizer, HIV disease progression rates, Acquisition, Patient, Laboratory, Immunoglobulin G, Diagnosis, Matrix-assisted laser desorption/ionization, World Health Organization, Medical device, Medical imaging, Fine chemical

Thermo Fisher Scientific, the world leader in serving science, today announced the commercial launch of the EXENT® Solution, after receiving IVDR certification*.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the commercial launch of the EXENT® Solution, after receiving IVDR certification*.
  • The EXENT Solution is now commercially available in the following countries: Belgium, France, Germany, Italy, the Netherlands, Spain and United Kingdom.
  • “The EXENT Solution represents a significant breakthrough in innovation for the detection and monitoring of monoclonal immunoglobulins,” said Dr. Stephen Harding, Chief Scientific Officer, Protein Diagnostics, Thermo Fisher.
  • Earlier this year, Thermo Fisher Scientific completed the acquisition of The Binding Site, adding protein diagnostics solutions, including diagnosis and monitoring for monoclonal gammopathies, to its specialty diagnostics portfolio.

Thermo Fisher Scientific Reports First Quarter 2023 Results

Retrieved on: 
Wednesday, April 26, 2023
Science, Other Science, Research, San Francisco, Partnership, Food, University, Applied Biosystems, Drink, Table, University of California, San Francisco, COVID-19, TMO, GAAP, Thermo Fisher Scientific, Binding site, COVID-19 testing, Element, Acquisition, Soil, UCSF, CGMP, Water, Invitrogen, EPS, PPI, Mindful Scientific Inc., NYSE, PCR, Management, Video game, Pharmaceutical industry

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 1, 2023.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 1, 2023.
  • GAAP operating income for the first quarter of 2023 was $1.56 billion, compared with $2.82 billion in the year-ago quarter.
  • Adjusted operating income for the first quarter of 2023 was $2.33 billion, compared with $3.45 billion in the year-ago quarter.
  • Thermo Fisher Scientific will hold its earnings conference call today, April 26, 2023, at 8:30 a.m. Eastern Time.

Nordic Capital acquires majority share in corpuls to support further development of the high-growth med-tech company

Retrieved on: 
Wednesday, April 19, 2023
Telehealth, Partnership, Corpulence index, Health care, SME, Research, Binding site, EUR, Patient, Advanz Pharma, Growth, Defibrillation, Nursing care plan, Medical device, Renewable energy, Pharmaceutical industry, DACH, Nordic Capital

STOCKHOLM, April 19, 2023 /PRNewswire/ -- Nordic Capital has agreed to acquire a majority share in corpuls to support the Company's next phase of growth, in partnership with the founding family.

Key Points: 
  • STOCKHOLM, April 19, 2023 /PRNewswire/ -- Nordic Capital has agreed to acquire a majority share in corpuls to support the Company's next phase of growth, in partnership with the founding family.
  • The Company is one of Germany's fastest growing mid-market companies due to an innovative product portfolio and pronounced research & development capabilities.
  • The founding family of corpuls is committed to a long-term partnership with Nordic Capital and will remain invested in the company and represented on the management board.
  • "We are excited to partner with Nordic Capital with the objective of jointly supporting the next stage of corpuls' growth.

One Community, One Question: What Is Your #MYelomaSTORY?

Retrieved on: 
Thursday, April 6, 2023
GSK, Wellness, MSN, MAM, International Myeloma Foundation, Regeneron Pharmaceuticals, Multiple myeloma, Social media, Hope, Bristol Myers Squibb, Marketing, Movement, Mindfulness, Organization, Takeda Oncology, Janssen Pharmaceuticals, Patient, AbbVie, Sanofi, RN, Diagnosis, Johnson & Johnson, Empathy, Region, Binding site, Wall, FAAN, IMF, Disease, Cryptocurrency, Online shopping, Food industry, Nursing, Pfizer

Messages of hope and resilience resonated across the global myeloma community—clearly showing that myeloma has no borders,” said IMF VP of Marketing Peter Anton.

Key Points: 
  • Messages of hope and resilience resonated across the global myeloma community—clearly showing that myeloma has no borders,” said IMF VP of Marketing Peter Anton.
  • Overwhelming participation in IMF in-person events: the Regional Community Workshop in San Diego, CA, and Patient Family Seminar in Boca Raton.
  • The IMF 31-Day Wellness Challenge where over 40 Support Groups logged over 45,000 minutes of movement, mindfulness, and self-care.
  • An abundance of shared snapshots from members of the myeloma community using the MAM website photo uploader.

International Myeloma Foundation (IMF) Launches #MYelomaSTORY Campaign for Myeloma Action Month in March 2023

Retrieved on: 
Thursday, February 23, 2023
Social media, Public service announcement, GSK, PSA, Amgen, International Myeloma Foundation, MSN, Disease, RN, Multiple myeloma, Research, Regeneron Pharmaceuticals, FAAN, Q&A, Patient, Radio, Support group, Education, Movement, IMF, Sanofi, African Americans, MAM, Binding site, Bristol Myers Squibb, Takeda Oncology, Cryptocurrency, Management, Communications satellite, Tourism, Nursing, Pfizer

STUDIO CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- With the International Myeloma Foundation (IMF) at the forefront, Myeloma Action Month is held every year for the whole month of March to encourage individuals and groups to take actions that positively impact the myeloma community.

Key Points: 
  • STUDIO CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- With the International Myeloma Foundation (IMF) at the forefront, Myeloma Action Month is held every year for the whole month of March to encourage individuals and groups to take actions that positively impact the myeloma community.
  • The IMF will engage the global myeloma community by sharing stories about members of the myeloma community who live well with myeloma and by prompting others to share their stories.
  • Using the #MYelomaSTORY hashtag, all related posts will be displayed on the IMF’s digital “Wall of Stories” at the Myeloma Action Month website: mam.myeloma.org.
  • This year during March Action Month we work together, take accountability, in increase the visibility of Myeloma and take action through your #MYelomaSTORY and whole wellness within ourselves.

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2022 Results

Retrieved on: 
Wednesday, February 1, 2023
Other Manufacturing, Research, Medical Devices, Manufacturing, Biotechnology, Health, Pharmaceutical, Other Science, Science, EPS, COVID-19 testing, Thermo Fisher Scientific, Veteran, TMO, Applied Biosystems, Immunotherapy, Vignan's Foundation for Science, Technology & Research, PPD, Binding site, NYSE, Drug development, Acquisition, Table, Patient, GAAP, Mindful Scientific Inc., Culture, ESG, Central Vermont Community Action Council, Student, Gas chromatography, FDA, COVID-19, STEM, Video game, Music, Thermoplastic, Management, Fine chemical, Core

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2022.
  • GAAP operating income for the fourth quarter of 2022 was $1.86 billion, compared with $2.54 billion in the year-ago quarter.
  • Adjusted EPS in the fourth quarter of 2022 was $5.40, versus $6.54 in the fourth quarter of 2021.
  • Adjusted operating income for the fourth quarter of 2022 was $2.56 billion, compared with $3.16 billion in the year-ago quarter.

Thermo Fisher Scientific Completes Acquisition of The Binding Site Group

Retrieved on: 
Tuesday, January 3, 2023
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Thermo Fisher Scientific, Mindful Scientific Inc., Nordic Capital, Lymphatic system, Binding site, Disease, TMO, Acquisition, NYSE, Binding, Multiple myeloma, Diagnosis, Medical imaging

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has completed its acquisition of The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.3 billion, or $2.8 billion at current exchange rates.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has completed its acquisition of The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.3 billion, or $2.8 billion at current exchange rates.
  • Thermo Fisher announced the agreement to acquire The Binding Site on October 31, 2022 .
  • “We are very excited to welcome The Binding Site colleagues to Thermo Fisher Scientific,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher.
  • “The Binding Site expands our existing specialty diagnostics portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma.

Thermo Fisher Scientific Continues to Execute Proven Capital Deployment Strategy

Retrieved on: 
Monday, October 31, 2022
Science, Other Science, Biotechnology, Pharmaceutical, Health, Medical Devices, Health Technology, Other Health, Invitrogen, PPD, Share repurchase, Intellectual property, Government, Thermo Fisher Scientific, Research, West Pharmaceutical Services explosion, U.S. Securities and Exchange Commission, TMO, SEC, NYSE, Patheon, SEC filing, Applied Biosystems, Growth, Acquisition, Fisher Scientific, Form 10-K, Binding site, Communication, Mindful Scientific Inc., Annual report, COVID-19, Health, Laboratory, Science, Renewable energy, Risk management

Thermo Fisher Scientific Inc. (NYSE: TMO) (Thermo Fisher), the world leader in serving science, today provided an update on capital deployment.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO) (Thermo Fisher), the world leader in serving science, today provided an update on capital deployment.
  • Throughout the fourth quarter of 2022, Thermo Fisher expects to execute a $1.0 billion share repurchase program, bringing the total capital deployed on buybacks to $3.0 billion in 2022.
  • Thermo Fisher continues to execute its disciplined capital deployment strategy through a combination of strategic M&A and return of capital to shareholders.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.